REGENERON'S REGEN-COV2 IS FIRST ANTIBODY COCKTAIL FOR COVID-19 TO RECEIVE FDA EMERGENCY USE AUTHORIZATIONhttps://investor.regeneron.com/index.php/news-releases/news-release-details/regenerons-regen-cov2-first-antibody-cocktail-covid-19-receiveRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the antibody cocktail casirivimab and imdevimab administered together (also known as REGN-COV2 or REGEN-COV2), a therapy currently being investigated for use in COVID-19, has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). Casirivimab and imdevimab administered together are authorized for the treatment of mild to moderate COVID-19 in adults, as well as in pediatric patients at least 12 years of age and weighing at least 40 kg, who have received positive results of direct SARS-CoV-2 viral testing and are at high risk for progressing to severe COVID-19 and/or hospitalization. The clinical evidence from Regeneron's outpatient trial suggests that monoclonal antibodies such as REGEN-COV2 have the greatest benefit when given early after diagnosis and in patients who have not yet mounted their own immune response or who have high viral load.
I've been expecting this EUA approval for several weeks. This makes the second monoclonal antibody (mab) treatment that has received EUA. These aren't a
Virus-Shattering-Kaboom but are a significant SARS-CoV-2 targeted treatment that have shown effectiveness. REGN-COV2 is the treatment Trump received.
The good thing about the timing of this EUA and the EUA for the Eli Lilly mab treatment is that it's early enough that if Biden is the next President, he can't F up the distribution of these treatments
(like I think he might with vaccines distribution, growl!!!)!
